title: Melanoma treatment's changing landscape.
authors.forename: Susan
authors.initials: S
authors.lastname: Jenks
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D017277:Drug Approval; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D007680:Kidney Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D009367:Neoplasm Staging; D000077594:Nivolumab; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000473:pathology; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000077594:Nivolumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf